Results 311 to 320 of about 154,739 (326)

IDH Inhibition

Clinical Lymphoma Myeloma and Leukemia, 2020
openaire   +2 more sources

Prediction of Ki-67 labeling index, ATRX mutation, and MGMT promoter methylation status in IDH-mutant astrocytoma by morphological MRI, SWI, DWI, and DSC-PWI

European Radiology, 2023
Xiefeng Yang, Chengcong Hu, Zhen Xing, Yu Lin, Yanqing Su, Xingfu Wang, D. Cao   +6 more
semanticscholar   +1 more source

TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma

Acta Neuropathologica, 2021
K. Fujimoto, Hideyuki Arita, K. Satomi, K. Yamasaki, Y. Matsushita, Taishi Nakamura, Y. Miyakita, Toru Umehara, Keiichi Kobayashi, Kaoru Tamura, Shota Tanaka, Fumi Higuchi, Y. Okita, Y. Kanemura, J. Fukai, Daisuke Sakamoto, T. Uda, R. Machida, A. Kuchiba, T. Maehara, M. Nagane, R. Nishikawa, Hiroyoshi Suzuki, M. Shibuya, T. Komori, Y. Narita, K. Ichimura   +26 more
semanticscholar   +1 more source

IDH Snippets

2017
P. Anandan, Vidya Natampally, Srinivasa Ranganathan   +2 more
openaire   +1 more source

Glioblastoma IDH wildtype - multifocal

2023
openaire   +1 more source

IDH mutated gliomas

Journal of the Neurological Sciences, 2021
openaire   +1 more source

Genetic variation between IDH mutant and IDH wild-type glioma

WFNOS 2022 Abstract Book, 2022
Shaoqun Li, Mingyao Lai, Linbo Cai
openaire   +1 more source

IDH Inhibitors for the Treatment of IDH-Mutated Cancer

2019
Lenny Dang, Brandon Nicolay, Zenon Konteatis   +2 more
openaire   +1 more source

Glioblastoma, IDH-wildtype

2022
openaire   +1 more source

[Ⅳ. IDH Inhibitor].

Gan to kagaku ryoho. Cancer & chemotherapy, 2022
Fumiya, Wada, Tadakazu, Kondo
openaire   +1 more source